DEFA14A: Metsera Responds to Pfizer Litigation Amidst Acquisition Bid

Metsera, Inc. has issued a statement disagreeing with Pfizer's litigation allegations, vowing to address them in court.

Summary

• Metsera, Inc. (NASDAQ: MTSR) has formally responded to litigation filed against it by Pfizer Inc. on October 31, 2025.
• Metsera explicitly disagrees with the allegations made in Pfizer's complaint.
• The company intends to address these allegations in the Delaware Court of Chancery.
• The litigation is occurring in the context of Pfizer's proposed acquisition of Metsera and an unsolicited proposal from Novo Nordisk A/S.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the announcement of litigation from Pfizer, which introduces significant uncertainty, potential costs, and risks to the proposed acquisition and Metsera's operations. While Metsera states disagreement, the existence of litigation is inherently adverse.

Negatives

• Pfizer has filed litigation against Metsera, creating legal and financial uncertainty.
• The litigation could result in significant expenses for defending the case.
• There is a potential for damages or other losses if the litigation is unsuccessful for Metsera.
• The litigation may negatively impact Metsera's business, its market price, and the ongoing acquisition proposals.
• The proposed acquisition faces risks including failure to obtain regulatory approvals or stockholder vote, and the possibility of not closing at all.

Risks

• Expenses from defending the litigation filed by Pfizer Inc.
• Potential damages or other losses resulting from the litigation.
• Impact of the litigation on Metsera, its business, and the market price of its common stock.
• Impact of the litigation on Novo Nordisk A/S's unsolicited proposal.
• Failure to obtain necessary regulatory approvals for the proposed acquisition.
• Failure to obtain the requisite vote by Metsera stockholders for the proposed acquisition.
• Possibility that the proposed acquisition does not close in the anticipated timeframe or at all.
• Possibility that more competing offers may be made, complicating the acquisition process.
• Inability to realize the anticipated benefits of the proposed acquisition.
• Risk that the businesses will not be integrated successfully post-acquisition.
• Disruption from the transaction making it more difficult to maintain business and operational relationships.
• Difficulty in attracting and retaining highly qualified management and other clinical and scientific personnel.
• Negative effects of the acquisition announcement or consummation on the market price of Pfizer's or Metsera's common stock and/or operating results.
• Significant transaction costs associated with the proposed acquisition.
• Unknown liabilities that may arise from the acquisition or litigation.
• Risk of additional litigation and/or regulatory actions related to the proposed acquisition or Metsera's business.
• Uncertainties regarding the commercial success of Metsera's or Pfizer's pipeline products.
• Risks associated with conducting clinical trials and preclinical studies, including side effects, adverse events, and safety risks of product candidates.
• Challenges in obtaining, maintaining, defending, and enforcing patent or other intellectual property protection.
• Uncertainties inherent in research and development, including meeting anticipated clinical endpoints, trial completion dates, and regulatory approvals.

Future Outlook

The filing contains forward-looking statements regarding Pfizer's proposed acquisition of Metsera, the companies' pipeline products, potential clinical trials, and the anticipated timing of the acquisition. It also highlights substantial risks and uncertainties that could cause actual results to differ materially from these statements, including those related to the ongoing litigation and the challenges of integrating businesses and obtaining regulatory approvals.

Management Comments

• "Metsera disagrees with the allegations in Pfizer's complaint and will address them in the Delaware Court of Chancery."

Industry Context

This announcement highlights the competitive and legally complex landscape of pharmaceutical mergers and acquisitions. Litigation between an acquiring company and a target company, especially concerning intellectual property or contractual obligations, is a significant event that can disrupt or derail high-value transactions in the biotech and pharma sectors. The mention of an unsolicited proposal from Novo Nordisk further underscores the intense competition for valuable assets in the industry.

Legal Proceedings

• Pfizer Inc. has filed litigation against Metsera, Inc. Metsera disagrees with the allegations and will address them in the Delaware Court of Chancery.

Stakeholder Impact

• Shareholders: Potential negative impact on stock price due to litigation uncertainty, and the need to review proxy statements for voting decisions on the proposed acquisition.
• Employees: Potential disruption from the transaction making it more difficult to maintain business and operational relationships, including attracting and retaining highly qualified management and clinical/scientific personnel.
• Acquiring Parties (Pfizer, Novo Nordisk): The litigation adds complexity and risk to the proposed acquisition, potentially affecting its timing, terms, or even its completion.

Next Steps

• Metsera will address the allegations made by Pfizer Inc. in the Delaware Court of Chancery.
• Investors and security holders are urged to read preliminary and definitive proxy statements and other related documents filed with the SEC concerning the proposed acquisition before making any voting decisions.

Key Dates

Recommendation

The announcement of litigation from Pfizer against Metsera introduces significant uncertainty regarding the proposed acquisition and Metsera's future. While Metsera intends to defend itself, the potential for legal costs, damages, and disruption to the acquisition process warrants a cautious 'hold' recommendation. Investors should await further developments in the litigation and the acquisition process before making definitive investment decisions.

Keywords

Metsera, Pfizer, Litigation, Acquisition, Merger, SEC Filing, Corporate Governance, Pharmaceutical, Biotech, MTSR, Delaware Court of Chancery, Novo Nordisk